Some previous research studies have suggested that selonsertib (an inhibitor of ASK1) reduces fibrosis in NASH patients with fibrosis, whereas the improvement appears to be limited (Loomba et al., 2018; Harrison et al., 2020). The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.